Germany · Delayed Price · Currency is EUR ODI Pharma AB Statistics
Total Valuation
ODI Pharma AB has a market cap or net worth of EUR 2.64 million. The enterprise value is 2.38 million.
| Market Cap | 2.64M |
| Enterprise Value | 2.38M |
Important Dates
The last earnings date was Thursday, November 27, 2025.
| Earnings Date | Nov 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 18.33M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +26.93% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 90.83% |
| Owned by Institutions (%) | n/a |
| Float | 1.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.26 |
| PB Ratio | 99.71 |
| P/TBV Ratio | 99.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.83 |
| EV / Sales | 2.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.04
| Current Ratio | 1.04 |
| Quick Ratio | 1.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.44 |
Financial Efficiency
Return on equity (ROE) is -1,098.61% and return on invested capital (ROIC) is -609.93%.
| Return on Equity (ROE) | -1,098.61% |
| Return on Assets (ROA) | -37.12% |
| Return on Invested Capital (ROIC) | -609.93% |
| Return on Capital Employed (ROCE) | -1,367.10% |
| Revenue Per Employee | 810,279 |
| Profits Per Employee | -407,226 |
| Employee Count | 1 |
| Asset Turnover | 1.33 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ODI Pharma AB has paid 382 in taxes.
| Income Tax | 382 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.35% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -28.35% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.14 |
| Relative Strength Index (RSI) | 66.88 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ODI Pharma AB had revenue of EUR 810,279 and -407,226 in losses. Loss per share was -0.02.
| Revenue | 810,279 |
| Gross Profit | 198,365 |
| Operating Income | -361,734 |
| Pretax Income | -406,844 |
| Net Income | -407,226 |
| EBITDA | -361,571 |
| EBIT | -361,734 |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 261,078 in cash and n/a in debt, giving a net cash position of 261,078.
| Cash & Cash Equivalents | 261,078 |
| Total Debt | n/a |
| Net Cash | 261,078 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 26,460 |
| Book Value Per Share | 0.00 |
| Working Capital | 26,090 |
Cash Flow
| Operating Cash Flow | -354,938 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 24.48%, with operating and profit margins of -44.64% and -50.26%.
| Gross Margin | 24.48% |
| Operating Margin | -44.64% |
| Pretax Margin | -50.21% |
| Profit Margin | -50.26% |
| EBITDA Margin | -44.62% |
| EBIT Margin | -44.64% |
| FCF Margin | n/a |
Dividends & Yields
ODI Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.93% |
| Shareholder Yield | -26.93% |
| Earnings Yield | -15.43% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |